Market Overview

Market Research Future (MRFR) estimates the global paranasal sinus cancer market to garner a CAGR of 5.2% during the assessment period of 2018–2023.
Paranasal sinus cancer is an extremely rare case of cancer in which cells of the paranasal sinuses and nasal cavity develop malignancy. Dust and certain chemical agents in the air can cause paranasal sinuses cancer. Increase in air pollution and growing prevalence of chronic disease among people can spur the risk of developing paranasal sinuses cancer. These factors can fuel the paranasal sinus cancer market. The rise in geriatric population is another factor identified to boost the market growth. According to the American Cancer Society, 4 out of 5 paranasal sinus cancer cases are of atleast 55 years old.

Collaboration strategies can have powerful impact on the market growth. For example, in 2018, development and marketing of digital clinical decision support solutions, was the outcome of GE Healthcare’s partnership with Roche Diagnostics.

Fill Out Details To Receive FREE Sample Here: https://www.marketresearchfuture.com/sample_request/7514

Key Players
Important companies operating in the market are AbbVie, Inc., Pfizer Inc., Eli Lilly & Company, Novartis AG, Ipsen Biopharmaceuticals Inc, G E Healthcare, Agilent Technologies Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd., Abbott, Becton, Dickinson & Company, Thermo Fisher Scientific, and Bayer AG.